Fate Therapeutics (FATE) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$215.4 million.
- Fate Therapeutics' Enterprise Value rose 2744.82% to -$215.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$215.4 million, marking a year-over-year increase of 2744.82%. This contributed to the annual value of -$279.1 million for FY2024, which is 1145.62% up from last year.
- Per Fate Therapeutics' latest filing, its Enterprise Value stood at -$215.4 million for Q3 2025, which was up 2744.82% from -$222.8 million recorded in Q2 2025.
- Fate Therapeutics' 5-year Enterprise Value high stood at -$215.4 million for Q3 2025, and its period low was -$790.1 million during Q1 2021.
- Its 5-year average for Enterprise Value is -$434.7 million, with a median of -$383.5 million in 2024.
- Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 28868.53% in 2021, then surged by 3731.49% in 2025.
- Quarter analysis of 5 years shows Fate Therapeutics' Enterprise Value stood at -$615.9 million in 2021, then increased by 29.17% to -$436.2 million in 2022, then rose by 27.75% to -$315.2 million in 2023, then increased by 11.46% to -$279.1 million in 2024, then rose by 22.81% to -$215.4 million in 2025.
- Its Enterprise Value was -$215.4 million in Q3 2025, compared to -$222.8 million in Q2 2025 and -$240.4 million in Q1 2025.